Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2024-08-27 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled '云南沃森生物技术股份有限公司2024 年半年度报告摘要' which translates to 'Yunnan Walvax Biotechnology Co., Ltd. 2024 Semi-Annual Report Summary'. It contains detailed financial data such as revenue, net profit, cash flow, earnings per share, and asset information for the half-year period of 2024. It also discusses shareholder information, share repurchase and cancellation activities, and financing plans. The length of the document is 8597 characters, which is substantial and contains actual financial data and analysis, not just an announcement or summary. The content aligns with a comprehensive interim or quarterly financial report rather than a brief announcement or other filing types. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-27 Chinese
2024年半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 90% confidence The document is a summary table detailing non-operating fund occupation and other related party fund transactions for the half-year period of 2024 by Yunnan Watson Biotechnology Co., Ltd. It includes financial figures such as balances, interest, and repayments related to these transactions. The document is relatively short (1580 characters) and contains specific financial data for a half-year period, indicating it is a financial report rather than an announcement. The content focuses on related party transactions and fund usage, which is typical of disclosures found in Interim / Quarterly Reports. There is no indication that this is an announcement of a report or a certification letter, so it should not be classified as RPA or RNS. Therefore, the most appropriate classification is Interim / Quarterly Report (IR). H1 2024
2024-08-27 Chinese
2024年上半年募集资金存放与实际使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled '云南沃森生物技术股份有限公司 2024 年上半年募集资金存放与实际使用情况专项报告', which translates to 'Yunnan Watson Biotechnology Co., Ltd. 2024 First Half Year Special Report on the Deposit and Actual Use of Raised Funds'. The content details the amount of funds raised, their deposit in special accounts, usage, changes in investment projects, and compliance with regulatory requirements. It includes detailed financial figures related to fundraising and usage, as well as regulatory approvals and board meeting decisions regarding the use of raised funds. The document is a specialized report focused on the management and use of capital raised through share issuance and asset purchase, which aligns with the category of Capital/Financing Update (CAP). It is not a full annual or interim report, nor an earnings release or audit report. It is a detailed report on fundraising and capital usage, not merely an announcement or certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-08-27 Chinese
关于召开2024年半年度业绩网上说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of a half-year performance online briefing (业绩网上说明会) for the company Yunnan Watson Biotechnology Co., Ltd. It references the prior disclosure of the company's 2024 half-year report but does not contain the report itself or detailed financial data. The document invites investors to attend the online meeting to discuss the half-year results. This is a notice about an investor presentation event rather than the presentation or report itself. Therefore, the document fits best under the category of Investor Presentation (IP). The document length is short and it is clearly an announcement of a meeting, not the full transcript or report, so it is not an Interim Report (IR) or Earnings Release (ER).
2024-08-27 Chinese
关于公司收到发明专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of an invention patent certificate issued by the Chinese National Intellectual Property Administration. It details the patent name, number, type, application date, and the patent's significance to the company. There is no financial data, no mention of financial results, no regulatory filings related to financial performance, no shareholder voting results, no management changes, no capital or financing updates, and no legal proceedings. The document is a formal announcement about intellectual property rights, which does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings related to financial or corporate governance matters. It is a general regulatory announcement about a patent certificate. Given the absence of a more specific category, the best fit is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories. The document length is short and it is not an announcement of a report publication, so RPA is not appropriate. Confidence is high due to clear content and context.
2024-08-27 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 23rd meeting of the 5th Board of Directors of Yunnan Watson Biotechnology Co., Ltd. It includes details about the meeting date, attendance, and the voting results on several agenda items such as approval of the 2024 semi-annual report, fundraising usage report, impairment provisions, credit facilities for subsidiaries, and revisions to subsidiary management policies. The document does not contain the actual semi-annual report or detailed financial statements but refers to these reports being available on an external website (巨潮资讯网). The document is primarily a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). It is not a full financial report (like an Interim Report), nor is it a simple announcement of report publication (RPA), as it contains substantive board decisions and approvals. Therefore, the correct classification is MANG with high confidence.
2024-08-27 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.